Alnylam Pharmaceuticals (ALNY) Shares Gap Down After Earnings Miss

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $72.55, but opened at $76.05. Alnylam Pharmaceuticals shares last traded at $74.49, with a volume of 27450 shares traded.

The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($0.41). The company had revenue of $2.07 million during the quarter, compared to the consensus estimate of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The company’s revenue for the quarter was down 87.9% on a year-over-year basis. During the same period last year, the business posted ($1.34) EPS.

Several analysts recently issued reports on ALNY shares. BidaskClub raised Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, July 13th. Piper Jaffray Companies reissued an “overweight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 23rd. Cowen reissued a “buy” rating and issued a $157.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, August 2nd. BMO Capital Markets reissued a “buy” rating and issued a $127.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 3rd. Finally, Chardan Capital reissued a “buy” rating and issued a $180.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $142.94.

In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the sale, the chief operating officer now owns 1,916 shares of the company’s stock, valued at approximately $229,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of Alnylam Pharmaceuticals by 0.4% during the 2nd quarter. FMR LLC now owns 15,078,361 shares of the biopharmaceutical company’s stock valued at $1,485,068,000 after purchasing an additional 52,653 shares during the period. Baillie Gifford & Co. increased its position in shares of Alnylam Pharmaceuticals by 10.4% during the 2nd quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after purchasing an additional 397,668 shares during the period. BB Biotech AG increased its position in shares of Alnylam Pharmaceuticals by 20.2% during the 3rd quarter. BB Biotech AG now owns 1,370,538 shares of the biopharmaceutical company’s stock valued at $119,949,000 after purchasing an additional 230,000 shares during the period. Point72 Asset Management L.P. increased its position in shares of Alnylam Pharmaceuticals by 49.4% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock valued at $133,593,000 after purchasing an additional 448,362 shares during the period. Finally, First Trust Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 42.0% during the 3rd quarter. First Trust Advisors LP now owns 937,025 shares of the biopharmaceutical company’s stock valued at $82,008,000 after purchasing an additional 277,259 shares during the period. 90.37% of the stock is currently owned by hedge funds and other institutional investors.

The stock has a market cap of $8.69 billion, a PE ratio of -13.36 and a beta of 2.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22.

TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/10/alnylam-pharmaceuticals-alny-shares-gap-down-after-earnings-miss.html.

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Further Reading: How to calculate the intrinsic value of a stock

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply